Month: February 2019

The report namely Global Garcinia Cambogia Extract Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023 focuses on emerging market trends and provides emerging opportunities in the market and the future impact of major drivers and challenges. It supports decision makers in making cost-effective business decisions. The report will help players in developing effective strategies to optimize their effective positions. Current and future trends are outlined to determine the overall attractiveness and gain a stronger foothold in the Garcinia Cambogia Extract industry. Further future industry supply, market demand, value, competition and its analysis of key player with industry forecast from 2018 to 2023 is covered in the report.

According to the report, the Garcinia Cambogia Extract market is projected to accomplish a very fortunate valuation portfolio by the end of the estimated duration. Additionally, the study summarizes that this vertical will register a highly noteworthy growth rate over the forecast timeframe. Further, key aspects including advertise drivers, challenges, openings, future guide, key patterns, player profiles, procedures, and esteem chain are empowered in the report.

Request For Sample : https://marketandresearch.biz/sample-request/59417

The report is a crucial source for each market fan, policymaker, speculator, and other players. Complete information of these manufacturers and their market share by various regions, with the company and product introduction, is included in the report. It considers the market expanse, trade share, evolution, crucial areas, CAGR, and respective key drivers. The report includes relevant factors of participants such as product/service contributions, manufacturing process, capacity, income details, business synopsis, new product launches, acquisitions, and partnership. Numerous prominent companies cited in the report are

Xi’an Lyphar Biotech

Shaanxi Fuheng (FH) Biotechnology

Shaanxi Guanjie Technology

Wuhan Vanz Pharm

Hunan Kanerga Pharmaceutical Sales

TWO BLUE DIAMONDS

MARUTI FUTURISTIC PHARMA

KINAL GLOBAL CARE

NUTRA GRACE

Research Methodology:

The Garcinia Cambogia Extract market analysis is held using a standard and the tailored research methodology approach. The market gauges and estimates were determined through a mix of crucial and optional research. The varied sources used for integrates technical journals, paid data sources, annual reports, company websites, and other industry distributions.

To pursue the regional and international market, all the predictions of the industry report were quantity-wise as well as quality-wise considered. Geographically, this report is split into some important regions, together with production, consumption, revenue (USD), along with a market share in those regions, by 2013 to 2023, covering

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Download Full Copy : https://marketandresearch.biz/report/59417/global-garcinia-cambogia-extract-market-2018-by-manufacturers-regions-type-and-application-forecast-to-2023

Reasons For buying Garcinia Cambogia Extract Market Report:

• Detailed description before changing Garcinia Cambogia Extract elements that are focused is given by this report.
• The report has determined how the international market will grow during the anticipated period.
• It helps in the analysis of shifting competition aspects and keeps you facing of challenges.
• The report has mentioned elements limiting or producing Garcinia Cambogia Extract market progress
• It assists in to recognize the various segments as well as their potential.

About Us

Marketandresearch.biz is a leading global Market Research agency providing expert research solutions, trusted by the best. We understand the importance of knowing what global consumers watch and buy, further using the same to document our distinguished research reports. Marketandresearch.biz has worldwide presence to facilitate real market intelligence using latest methodology, best-in-class research techniques and cost-effective measures for world’s leading research professionals and agencies.

Contact Us:
Mark Stone (Sales Manager)
Phone: +1-201-465-4211
Email: [email protected]
Web: https://marketandresearch.biz/

NUTRAFUELS, INC. (OTCMKTS:NTFU) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01Entry into a Material Definitive Agreement.

On February 4, 2019, NutraFuels, Inc. a Florida corporation (“NTFU”), created a wholly owned subsidiary known as Phytochem Technologies, Inc. (“Phytochem”). Additionally, on February 4, 2019, Phytochem entered into an agreement (the “Agreement”) with Owen Morgan, an individual where by Mr. Morgan will provide certain know how and services to Phytochem for the commercializationofcertain technologies (the “Technology”) to separate and/or process the components of hemp to remove and/or modify, purify, dilute and extract bioactive ingredients and/or remove unwanted substances to produce finished products for a variety of applications.

Mr. Morgan is obligated to provide services to Phytochem for a period of one (1) year. In exchange for his services, Mr. Morgan received $65,520 USD upon execution of the Agreement and will be compensated $15,000 USD monthly. Mr. Morgan’s services include overseeing all aspects of the manufacturing which shall be done in the United Kingdom. Phytochem is obligated to pay up to $10,000 USD to manufacture a demo unit (“Demo Unit”) using the Technology and $400,000 plus enhancement costs, shipping and installation to manufacture two commercial units using the Technology.

Phytochem is obligated to pay Mr. Morgan 40% of net revenues derived from the commercialization of the Technology. In addition, Mr. Morgan shall receive shares of the Common Stock of NTFU upon certain milestones. Upon receipt of the Demo Unit and Commercial Unit, Mr. Morgan shall receive 500,000 and 1,500,000 shares, respectively. If the commercialization of the Technology results in revenues of $1,000,000, $5,000,000 and $10,000,000, Mr. Morgan shall receive 2,000,000 upon each milestone. If the commercialization of the Technology results in revenues of $25,000,000, $50,000,000, and $100,000,000, Mr. Morgan shall receive 4,000,000, 5,000,000 and 5,000,000 shares, respectively, upon each milestone.

The foregoing summary of the Agreement does not purport to be complete and is qualified in its entirety by reference to the Agreement, a copy of which is filed as Exhibit 10.24 to this report and incorporated herein by reference.

Forward Looking Statements

This Form 8-K contains statements of a forward-looking nature concerning NutraFuels, Inc. and its wholly owned subsidiary, Phytochem Technologies, Inc. (collectively the “Company”). These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by words or phrases such as “may,” “will,” “except,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. The Company has based these forward-looking statements largely on the Company’s current expectations and projections about future events and financial trends that the Company believes may affect the Company’s financial condition, results of operations, business strategy, and financial needs. There is no assurance that the Company’s current expectations and projections are accurate. All forward-looking statements in this press release are based on information available to the Company on the date hereof. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors are set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the section entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K with the Securities and Exchange Commission on April 17, 2018. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking statement. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under applicable law.

Item 9.01 Financial Statements and Exhibits

NUTRAFUELS INC Exhibit
EX-10.24 2 ntfu_ex1024.htm DEVELOPMENT COMMERCIALIZATION AGREEMENT ntfu_ex1024.htmEXHIBIT 10.24   DEVELOPMENT COMMERCIALIZATION AGREEMENT   This Agreement (“Agreement”) is made by and between PhytoChem Technologies,…
To view the full exhibit click here

About NUTRAFUELS, INC. (OTCMKTS:NTFU)

NutraFuels, Inc. manufactures and distributes oral spray nutritional and dietary products. The Company’s oral spray products are designed to provide more absorption than capsules or liquid formulas. Its products include NutraFuels sleep spray; NutraFuels Energy Spray; NutraFuels Garcinia Cambogia Spray; NutraFuels Headache and Pain Spray, and NutraFuels Hair, Skin and Nails Spray. Its NutraFuels Sleep Spray contains Melatonin, gamma-aminobutyric acid and Valerian Root. The Company’s Energize Spray contains B complex vitamins, B-12. The NutraFuels Energize Spray is designed to increase energy and restore vigor and vitality. Its Appetite and Weight management Spray contains Garcinia Cambogia. Its NutraFuels Garcinia Cambogia Spray is designed to suppress the appetite and boost metabolism. The NutraFuels Headache and Pain Spray contains turmacin, a natural anti-inflammatory. The NutraFuels Hair, Skin and Nails Spray is designed to nourish hair, skin and nail growth.

SCOTTSDALE, AZ, Feb. 06, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — CBD Life Sciences Inc. (“Company”) (OTC: OCSYD) is pleased to introduce our wholly owned subsidiary, LBC Bioscience Inc. and its cannabidiol based product line.

LBC Bioscience Inc.  (“LBC”), founded in August 2015 by Lisa A. Nelson, has developed a high-quality line of organic cannabidiol based supplements and wellness products. Current product sales consist of CBD based pain relief creams, massage oils, anti-anxiety and sleeping aids along with a line of pet products. In addition, LBC is developing a full line of skincare and anti-aging products.

What is CBD?

Cannabidiol (“CBD”) is a non-psychoactive compound extracted from the cannabis plant. The non-intoxicating marijuana extract is being credited with helping treat a host of medical problems, everything from epileptic seizures, anxiety, inflammation and sleeplessness. CBD continues to surge in popularity and is now gaining mainstream recognition. There are four typical ways to introduce the benefits of CBD into the human system: inhalation through vaporizers; topically through creams, soaps, shampoos and lotions; sublingually through oils, tinctures and concentrates; and by ingestion via pills and gummies.

The CBD Market

According to the most recent estimate from cannabis industry analysts the Brightfield Group, the CBD market could reach $22 billion by 2022.  LBC is positioning to become a leader in the CBD space by offering a comprehensive high-quality product line to the retail CBD market,  with the ability to white label their products for wholesalers. 

The LBC Product Line

LBC currently offers the following products for sale on its website at www.lbcbioscienceinc.com :

•  CBD Rich Hemp Oil Drops – helps with acne, arthritis, anxiety, chronic pain, depression, pain relief and more
•  CBD Hemp Oil Anxiety E Liquid – specially formulated to help reduce anxiety
•  CBD Hemp Oil Sleep E Liquid – specially formulated to help fall asleep
•  CBD Vitamin B12 Drops – formulated to increase energy and absorption
•  CBD Biotin Drops – promotes healthy skin, hair and nails
•  CBD Garcinia Cambogia Drops – helps suppress appetite, supports weight loss and helps break down fat
•  CBD Terpenes Tinctures – helps with acne, arthritis, anxiety, chronic pain, depression, pain relief and more
•  CBD Gummy Bears – take for pain relief, anti-inflammatory, stress and anxiety relief
•  CBD Pain Relief Cream – used for treatment of minor muscle and joint pain
•  CBD Freeze Pain Cold Rub Therapy – topical analgesic blended with raw CBD to soothe minor aches and pains
•  CBD Pet Supplement Drops – helps with arthritis and digestive issues
•  CBD Pet Treats – helps with arthritis, stress, and digestive issues
•  Pain Cream for Pets – topical solution for arthritis and acute elements like strains or torn ligaments

About CBD Life Sciences Inc.

CBD Life Sciences Inc. is a publicly traded company having its common shares quoted on the OTC Markets under the symbol ‘OCSYD’. The Company’s main focus is to identify, evaluate and acquire undervalued opportunities with the objective of increasing shareholder value. The acquisition of LBC Bioscience Inc. is the first in the CBD space and the company is actively searching  for additional opportunities within this emerging sector.

About LBC Bioscience Inc.  

LBC Bioscience Inc. is a wholly owned subsidiary of CBD Life Sciences Inc.  LBC is developing and marketing a line of cannabidiol based organic products such as hemp drops, massage oils, recovery pain relief creams, anxiety and sleep solutions, supplements, edibles, and a full line of pet products.  In addition, LBC is in the process of developing an anti-aging skin product line. LBC’s products can be viewed and purchased on the company’s website at www.lbcbioscienceinc.com.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See Optium Cyber Systems, Inc.’s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

Safe Harbor Statement

This release includes forward-looking statements, which are based on certain assumptions and reflects management’s current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information

Investor Relations

Ten Associates LLC

11529 N. 120th St.

Scottsdale, Arizona

85259 USA

Telephone: 480-326-8577

Contact: Thomas E. Nelson

Email: tenassociates33@gmail.com